Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 801–900 of 1,000
Effector and cytolytic function of natural killer cells in anticancer immunity
Karmakar, S., Mishra, A., Pal, P., & Lal, G. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad126 · Cited by 6
Serritella, A. V., Larrocha, P. S.-L., Dhar, P., Liu, S., Medd, M. M., Jia, S., Cao, Q., & Wu, J. D. (2024) · Biomedicines · doi:10.3390/biomedicines12010196 · Cited by 7
“It was demonstrated that mouse or human tumors with forced expression of membrane-bound NKG2D ligands can be rejected in vivo through activation of NK cells and sometimes CD8 T cells, heightening the significance of NKG2D stimulating in anti-tumor immunity [14,15].”
BackgroundLy49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model
Barber, M. A., Zhang, T., Gagne, B. A., Ginderachter, J. A. V., BAETSELIER, P. D., & Sentman, C. L. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0404-2 · Cited by 6
“in mice [4, 7].”
Pérez‐García, A., Pérez‐Durán, P., Wossning, T., Sernández, I. V., Mur, S. M., Cañamero, M., Real, F. X., & Ramiro, A. R. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505348 · Cited by 6
“…of the DNA damage response (DDR) pathway induces the expression of NKG2D ligands in epithelial cells, which are in turn recognized by NKG2D receptors expressed by NK cells and subsets of T cells (Diefenbach et al, 2001; Gasser et al, 2005; Champsaur & Lanier, 2010; Raulet et al, 2013).”
BackgroundAlgorithmic asymptotic analysis: Extending the arsenal of cancer immunology modeling
Patsatzis, D. G. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110975 · Cited by 6
Evolutionary Dynamics Optimal Research-Oriented Tumor Immunity Architecture
Sun, J., Yan, Y., Cheng, F., Wang, J., & Dang, Y. (2023) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2023.3297121 · Cited by 6
Shi, H., Li, Z., & Zhu, M. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673296618240424095548 · Cited by 6
Kapoor, S., Rallabandi, V. P. S., Sakode, C. M., Padhi, R., & Roy, P. K. (2013) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-10-68 · Cited by 6
IRF-1 is critical for IFNγ mediated immune surveillance
Ksienzyk, A., Neumann, B., & Kröger, A. (2012) · OncoImmunology · doi:10.4161/onci.19405 · Cited by 6
“Other studies have indicated NK cell activation by NKG2D ligands and other activating receptors like DNAXaccessory molecule-1 (DNAM-1) in the presence of MHC class I expression.(7,8) Recently it was reported that DNAM-1 together with other activating receptors induce NK cell mediated killing.”
BackgroundForeign or Domestic CARs: Receptor Ligands as Antigen-Binding Domains
Shaffer, D. R., Zhou, P., & Gottschalk, S. M. (2014) · Medical Sciences · doi:10.3390/medsci2010023 · Cited by 6
“These ligands provide optimal targets for immunotherapy because they are often overexpressed on tumor cells, but not by normal cells, and have been shown to mediate anti-tumor immunity in mice and humans [26,27].”
BackgroundBezouška, K. (2004) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc20040535 · Cited by 7
Correction: Cellular Expression, Trafficking, and Function of Two Isoforms of Human ULBP5/RAET1G
Eagle, R. A., Flack, G., Warford, A., Martínez-Borra, J., Jafferji, I., Traherne, J. A., Ohashi, M., Boyle, L. H., Barrow, A. D., Caillat‐Zucman, S., et al. (2009) · PLoS ONE · doi:10.1371/annotation/8501cd33-6c9e-437c-9ea1-f96fbb4140d6 · Cited by 6
Cancer vaccines: progress reveals new complexities
Yu, Z., & Restifo, N. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200216216 · Cited by 6
Comment on: A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
de Pillis, L. G., Radunskaya, A., & Wiseman, C. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1403 · Cited by 6
Dynamics of a stochastic tumor–immune interaction system
Wang, A., Xue, D., Wang, Z., Zhao, J., & Rao, F. (2024) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-024-05898-2 · Cited by 5
“(A1) The growth of tumor cells is logistic so r 1 T (1 − d 1 T ) where r 1 and d 1 denote the per capita growth rates and reciprocal carrying capacity of the tumor population [46, 47].”
Dynamics of a Model of Tumor–Immune Cell Interactions Under Chemotherapy
Alqahtani, R. T., Ajbar, A. M., & Aljebli, E. H. (2025) · Mathematics · doi:10.3390/math13132200 · Cited by 5
Li, W., Zhu, K., Xu, B., Nie, J., Wang, F., Aziz, A. U. R., Yu, X., Wang, D., & Ha, C. (2026) · Mediators of Inflammation · doi:10.1155/mi/9028037 · Cited by 6
“NKG2D recognizes stress-induced ligands such as MICA/ B and ULBPs [29, 30], reduced receptor expression, and elevated soluble ligands compromise target recognition and killing [30, 31].”
Natural killer cells swarm and cross-recruit cytotoxic T cells via CCR5
Cremasco, J., Tay, S. S., Yang, G., Huber, A., Kempe, D., Tang, R., Colakoglu, F., Newman, P. L. H., Lin, X., Goldstein, L. D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117415 · Cited by 5
Fišerová, A., Richter, J., Čapková, K., Bieblová, J., Mikyšková, R., Reiniš, M., & Indrová, M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3561 · Cited by 5
PRABHALA, R. H., & Munshi, N. C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.011 · Cited by 5
Zou, M., Al‐Yahya, S., Al-Alwan, M. M., BinEssa, H. A., Khabar, K. S. A., Almohanna, F., Assiri, A. M., Altaweel, A., Qattan, A. T., Meyer, B. F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171816 · Cited by 5
“Frontiers in Immunology 08 shown that the expression of NKG2D ligands on tumor cells renders them susceptible to killing by NK cells in vitro and the rejection of tumor xenografts in vivo (35, 36).”
BackgroundCytokine Intervention: A Double Edged Sword in the Nkg2d System Regulation
Montalban‐Arques, A. (2014) · Immunome Research · doi:10.4172/1745-7580.s2.002 · Cited by 6
Strategies of Natural Killer (NK) Cell Recognition and Their Roles in Tumor Immunosurveillance
Stewart, C. A., & Vivier, É. (2008) · Springer eBooks · doi:10.1007/978-4-431-73884-8_2 · Cited by 7
Tai, D., & Tai, J. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.54 · Cited by 5
“Some of the tumour cell may relieve soluble MICA molecules to block immune surveillance([45,46]).”
BackgroundReceptors of immune cells mediates recognition for tumors
Anang, V., Singh, A., Kottarath, S. K., & Verma, C. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.09.009 · Cited by 5
Jost, S., Ahn, J. J., Chen, S. L., Yoder, T., Gikundiro, K. E., Lee, E., Gressens, S. B., Kroll, K. W., Craemer, M., Kaynor, G. C., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad424 · Cited by 5
Ahsan, M. R., Mahmud-Al-Rafat, A., Sobhani, M.-E., & Molla, M. A. W. (2013) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-013-0075-y · Cited by 6
Peinado, C. D., Kang, X., Hardamon, C. R., Arora, S., Mah, S., Zhang, H., Ngolab, J., & Bui, J. D. (2013) · Immunology · doi:10.1111/imm.12080 · Cited by 5
Minor histocompatibility antigens: time for a paradigm shift?
Malarkannan, S. (2005) · Transplantation Reviews · doi:10.1016/j.trre.2005.02.001 · Cited by 5
“Further, both cd TCR+ and CD8+ ab TCR+ T cells also express functional NKG2D receptors [79,80].”
Wang, W., Bunyatov, M. I., Moffat, D., Lopez‐Barbosa, N., & DeLisa, M. P. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.07.007 · Cited by 4
Srisantitham, J., Thongsin, N., Suwanpitak, S., & Wattanapanitch, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334246 · Cited by 4
“Additionally, tumor cells normally downregulate MHC class I molecules to escape T cell recognition, allowing these cells to be detected and eliminated by NK cells [8,9].”
Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-β1 suppression
Chava, S., Bugide, S., Malvi, P., DeMarco, K. D., Ma, B., Parikh, C. N., Ruscetti, M. A., Zajac, A. J., Cai, G., Gupta, R., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00357-6 · Cited by 4
“Furthermore, it has been established that the quantitative level of NKG2D ligand expression de fi nes the “ threat ” level of target cells, and that it correlates with NK cell-dependent tumor elimination (Diefenbach et al, 2001; Raulet et al, 2013).”
ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity
Yamane, K., Yamaguchi, K., Teruya, Y., Miyake, N., Nakayama, Y., Nonaka, T., Chikumi, H., & Yamasaki, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072950 · Cited by 5
“Ectopic expression of murine NKG2D ligands on tumor cells enhances tumor immune elimination [9,10].”
Rojas‐Domínguez, A., Martínez-Vargas, I. U., & Alvarado, M. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109717 · Cited by 5
Steinle, A., & Cerwenka, A. (2015) · Science · doi:10.1126/science.aaa9842 · Cited by 4
Targeting the quiescent cells in cancer chemotherapy treatment: Is it enough?
Tridane, A., Yafia, R., & Aziz-Alaoui, M. A. (2015) · Applied Mathematical Modelling · doi:10.1016/j.apm.2015.12.023 · Cited by 4
Cancer Immunosurveillance by Natural Killer Cells and Other Innate Lymphoid Cells
Guillerey, C., & Smyth, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_9 · Cited by 5
Modelling Cancer Dynamics Using Cellular Automata
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2019) · STEAM-H: Science, Technology, Engineering, Agriculture, Mathematics & Health · doi:10.1007/978-3-030-15715-9_8 · Cited by 4
A NEW MATHEMATICAL MODELING AND SUB-OPTIMAL CHEMOTHERAPY OF CANCER
Darandis, N., & Nazari, M. (2021) · Journal of Biological Systems · doi:10.1142/s0218339021500133 · Cited by 4
Solís, F. J., & Gonzalez, L. M. (2023) · Nonlinear Dynamics · doi:10.1007/s11071-023-08616-2 · Cited by 4
“are supported by observations from [47], where the coefficient sl represents the saturation level of fractional infected cell killed by CD8+ T cells, the coefficientψ1 is the maximumCD8+ T cell recruitment rate, and finally, ψ2 represents the steepness coefficient of the CD8+ T cell recruitment.”
BackgroundMethodInfluentialPardoll, D. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00006-0 · Cited by 4
Ganesan, P. L., Alexander, S. I., Watson, D., Logan, G. J., Zhang, G. Y., & Alexander, I. E. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0339-7 · Cited by 4
“possible involvement of known ligands for the NKG2D receptor in this eVect, we excluded the presence of Rae-1, H60 and MULT-1 on both vector-control and CD80-transduced EL4 cells by Xow cytometry (data not shown) [6, 16].”
BackgroundJänner, N., Hahnke, K., Mollenkopf, H., Steinhoff, U., Kaufmann, S. H. E., & Mittrücker, H. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02817.x · Cited by 4
Nitric oxide signaling pathway activation inhibits the immune escape of pancreatic carcinoma cells
Lu, Y., Hu, J., Sun, W., Duan, X., & Chen, X. (2014) · Oncology Letters · doi:10.3892/ol.2014.2607 · Cited by 4
“They are rarely expressed by normal cells, however, are broadly expressed in a variety of malignancies (3-5).”
Imunovigilância e Imunoedição de Neoplasias: Implicações Clínicas e Potencial Terapêutico
Torrezini, T., & Athanazio, D. A. (2008) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2008v54n1.1762 · Cited by 4
Innate and adaptive immunity in cancer
Doshi, A. S., & Asrani, K. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00025-9 · Cited by 4
Minor histocompatibility antigens: molecular targets for adoptive cellular immunotherapy
Malarkannan, S. (2002) · Current Opinion in Organ Transplantation · doi:10.1097/00075200-200209000-00015 · Cited by 4
FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
Duhan, V., Gomez, M. R., Le, T. T., Rana, S., Chen, Y.-C. E., Balakrishnan, D., Kelly, G., Johnston, R. L., Krebs, P., & Khanna, R. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0174 · Cited by 3
Wang, S., Barry, A. M., Lee, Y. K., Young, N., Shim, S. W., Wang, X., Kim, H., Stirling-Barros, L., González‐Cano, R., Costigan, M., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03675-1 · Cited by 3
“Other known NKG2D ligands include the multi-gene family histocompatibility 60 ( H60) a-c [28] and murine UL16-binding protein-like transcript 1 Mult1 (Ulbp1) [29], which also contribute to NK cell-mediated cytotoxicity [30].”
The wonderous chaperones: A highlight on therapeutics of cancer and potentially malignant disorders
Tyagi, N., & Tyagi, R. (2015) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/0973-029x.164535 · Cited by 3
“Taking antitumor immunity as an example, the first line of defense is mediated by natural killer cells which are part of the innate immunity.[21,22] These cause lysis of the tumor cells and the cross‐presentation of antigens by dendritic cells (DCs) to prime adaptive T‐cells.”
BackgroundChen, Z., Cui, S., Dai, Y. D., Lu, C., Zhang, H., Zhao, W., Yan, H., & Zhang, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7595230 · Cited by 3
RetractedKir6.1, a component of an ATP-sensitive potassium channel, regulates natural killer cell development
Samper, N., Harðardóttir, L., Depierreux, D., Song, S. C., Nakazawa, A., Gando, I., Nakamura, T. Y., Sharkey, A., Nowosad, C. R., Feske, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1490250 · Cited by 3
Razmkhah, M., Mansourabadi, Z., Mohtasebi, M. S., Talei, A., & Ghaderi, A. A. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_866_16 · Cited by 3
“It has been shown that transplanted tumor cells expressing Rae1 and H60 were rejected in vivo.([15,16]) MIC B sheds by metalloproteases from tumor cells and releases to bloodstream or tissue culture medium as a soluble molecule in different malignancies.”
BackgroundHelmin–Basa, A., Gackowska, L., Balcerowska, S., Ornawka, M., Naruszewicz, N., & Wiese‐Szadkowska, M. (2020) · Physical Sciences Reviews · doi:10.1515/psr-2019-0058 · Cited by 5
NK Cells and ILC1s in Cancer Biology
Sliz, A., & Yokoyama, W. M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-8387-9_4 · Cited by 3
Engineering an energy-dissipating hybrid tissue in vivo for obesity treatment
Wang, L., Sun, Y., Yang, L., Wang, S., Liu, C., Wang, Y., Niu, Y., Huang, Z. D., Zhang, J., Wang, C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114425 · Cited by 3
Jin, Y., Guo, Y., Kawano, Y., Sasatani, M., Ohki, S., Yamane, K., Ota, Y., Tamura, Y., Sotomaru, Y., Baba, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597731 · Cited by 5
Current Perspectives on Immunomodulation of NK Cells in Melanoma
Lakshmikanth, T., & Maria, H. (2011) · InTech eBooks · doi:10.5772/23903 · Cited by 4
“The involvement of NK cells in antitumor immunity in vivo was demonstrated in several mouse tumor models using NK cell-depleting antibodies and genetically modified mutant mice (Diefenbach et al., 2001; Shankaran et al., 2001; Smyth et al., 2002).”
BackgroundPollock, R. A., Pellett, F., Chandran, V., & Gladman, D. D. (2011) · Tissue Antigens · doi:10.1111/j.1399-0039.2011.01764.x · Cited by 3
Concepts and Ways to Amplify the Antitumor Immune Response
Rubin, B., & Gairin, J. E. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_89 · Cited by 3
“The up-regulation of MHCI-like molecules alerts the immune system for the presence of damaged and potentially dangerous cells via NKG2D and other receptors (Diefenbach et al. 2001).”
BackgroundModeling Immune-Mediated Tumor Growth and Treatment
de Pillis, L. G., & Radunskaya, A. (2014) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-1-4939-0458-7_7 · Cited by 3
Role of Antibodies: A Novel Paradigm in Mathematical Modeling for Cancer TreatmentPreprint
Feyissa, S., & Banerjee, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1006.5069 · Cited by 3
NK Cells in Antitumor Immunity
Cerwenka, A., & Pahl, J. H. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17012-2 · Cited by 3
Expression, Prognosis, and Regulation of ULBP1, ULBP2, and ULBP3 in Human Breast CancerPreprint
Zhang, Y., Han, C., Shao, E., Sun, L., & Liu, D. (2021) · Research Square · doi:10.21203/rs.3.rs-574086/v1 · Cited by 3
McColl, I. (2004) · Wiley eBooks · doi:10.1002/0471684228.egp06229 · Cited by 3
Functional Specialization of Dendritic Cell Subsets
Heger, L., Amon, L., Lehmann, C. H. K., Barańska, A., Heidkamp, G. F., & Dudziak, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00257-1 · Cited by 4
Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients
Alamri, A. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00670-2 · Cited by 2
“MICA/MICB, ligands of NKG2D receptor, for example, are molecules, belonging to MHC 1 class which become up-regulated in virus-infected cells [66, 67].”
Howell, L. M., & Forbes, N. S. (2025) · Bioengineering · doi:10.3390/bioengineering12070751 · Cited by 2
“Both values are acquired from the modeling work of de Pillis et al., which calculates rate constants based on the experimental work of Diefenbach et al. [32,56,57].”
Goldufsky, J. W., Reyes, A. F., Heller, A., Leifheit, M. E., Albalawi, M., King, N. T., Kuzel, T. M., Schneider, J. R., & Marzo, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311490 · Cited by 2
“NKG2D-NKG2DL signals induce degranulation and/or cytokine production in cytotoxic effector cells [56,57].”
An analytical modeling framework for breast cancer progression and treatment evaluation
Gholami, H., Gachpazan, M., Erfanian, M., & Hasanzadeh, M. (2025) · Healthcare Analytics · doi:10.1016/j.health.2025.100441 · Cited by 2
Gupta, R. K., & Gupta, G. (2012) · Springer eBooks · doi:10.1007/978-3-7091-1065-2_31 · Cited by 2
Delitto, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00015-0 · Cited by 2
López, Á. G., & Sanjuán, L. R. (2023) · Fractals · doi:10.1142/s0218348x24500099 · Cited by 2
Mathematical modeling and bifurcation analysis for a biological mechanism of cancer drug resistance
Bao, K., Liang, G., Tian, T., & Zhang, X. (2024) · Acta Mathematica Scientia · doi:10.1007/s10473-024-0321-x · Cited by 2
Yang, Z., Li, J., Watanabe, H., Gao, F., Kawajiri, A., Koinuma, K., Sato, K., Okuyama, Y., Tayama, S., Iwakura, Y., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0598 · Cited by 2
Analysis of a combination of cancer treatments in efforts to overcome drug resistance
Omer, S., & Mambili‐Mamboundou, H. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110278 · Cited by 2
Diefenbach, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394802-1.00004-2 · Cited by 3
Self-citationNKG2D-Based Cancer Immunotherapy
Wu, J. D., & Wang, X. (2011) · InTech eBooks · doi:10.5772/23523 · Cited by 2
“…various origin, including the thymoma cell line EL4, the T- cell lymphoma cell line RMA, and the poorly immunogenic and highly metastatic melanoma variant B16-BL6, induced in vivo rejection or retarded tumor growth when implanted into syngeneic mice (Cerwenka et al., 2001; Diefenbach et al., 2001).”
BackgroundInfluentialStudies on the antigenicity of the NKG2D ligand H60a in tumour cells
Yadav, D., Ngolab, J., Dang, N., & Bui, J. D. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03427.x · Cited by 2
Das, B., Mushnitsky, R., & Norin, A. J. (2005) · Human Immunology · doi:10.1016/j.humimm.2005.01.003 · Cited by 2
Yip, J., Zhang, Z., & Jevnikar, A. M. (2012) · Scholarship@Western (Western University) · Cited by 2
Wei, H. (2016) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2016.21.1279 · Cited by 2
“For the term involving tumor lysis by CD8T cells, the experimental data from [12] indicates that the percentage of lysis is a function of the ratio of CD8T cells to tumor cells and the percentage does not exceed a maximum [10].”
BackgroundMethodA Mathematical Model for Tumor–Immune Dynamics in Multiple Myeloma
Gallaher, J. A., Larripa, K., Ledzewicz, U., Renardy, M., Shtylla, B., Tania, N., White, D., Wood, K., Zhu, L., Passey, C., et al. (2018) · Association for Women in Mathematics series · doi:10.1007/978-3-319-98083-6_5 · Cited by 4
“Pathway Description References a TC crosstalk with N; boosts N proliferation [6], [54], [58], [76], [77], [79] b N crosstalk with TC; boosts TC proliferation [6], [65], [76] c TC increases activation/efficacy of N [54], [58], [77] d Antigens shed from M stimulate TC proliferation [1], [21], [25], [39], [70], [95] e N…”
BackgroundEffects of Antibodies and Cytotoxic T-lymphocytes on Cancer: A Mathematical Study
Ghosh, S., & Banerjee, S. (2020) · International Journal of Applied and Computational Mathematics · doi:10.1007/s40819-020-00811-8 · Cited by 2
Stability analysis of endemic equilibrium points on cancer cells mathematical model
Arifah, H., Lestari, D., & Sari, E. R. (2020) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1581/1/012013 · Cited by 2
NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms
Dunai, C., Collins, C. P., Barão, I., & Murphy, W. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00001-1 · Cited by 3
Levels of Soluble NKG2D Ligands and Cancer History in Patients Starting Hemodialysis
Nagai, K., Tawara, T., Usui, J., Ebihara, I., Ishizu, T., Kobayashi, M., Maeda, Y., Kobayashi, H., & Yamagata, K. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.875207 · Cited by 2
“In these models, NKG2DLs expressed on tumor cells and bound to NKG2D can activate NK cells to kill tumor cells by means of perforin-based cytotoxicity (4, 5).”
BackgroundThe Expression of ARMCX1 in Gastric Cancer Contributes to Prognosis and Influences Chemotherapy
Lv, C., Yang, D., Zhang, D., Shen, J., Wang, Z., He, S., Meng, L., Song, J., & Zhao, J. (2023) · Journal of Immunology Research · doi:10.1155/2023/2623317 · Cited by 2
“central role in fibrotic processes in the liver, and defects in this pathway cause impaired NO-dependent responses in hepatic stellate cells on activation [52].”
BackgroundComplement-mediated killing of cancer cells
Hakulinen, J. (2003) · Työväentutkimus Vuosikirja · Cited by 2
Surgical Therapy for Atrial Fibrillation
Bolotin, G., & Maessen, J. G. (2008) · Springer eBooks · doi:10.1007/978-1-84800-104-6_15 · Cited by 2
Minor Histocompatibility Antigens: Molecular Barriers for Successful Tissue Transplantation
Malarkannan, S., & Pooler, L. M. (2004) · Springer eBooks · doi:10.1007/978-1-4419-8999-4_7 · Cited by 2
Modelling the response of cytotoxic t-lymphocytes in controlling solid tumour invasion.
Malinzi, J. (2013) · Cited by 2
Chen, Y., Zhou, Z., Zhu, W., Chen, G., Shi, Y., Lin, W., Guo, Z., & Ye, Y. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p61 · Cited by 2
On the fractional cell kill law governing the lysis of solid tumorsPreprint
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2016) · arXiv (Cornell University) · doi:10.48550/arxiv.1601.07144 · Cited by 2
Kill rates by immune cells: Ratio-dependent, or mass action?
Radunskaya, A., & Sack, J. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111748 · Cited by 1
Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors
Chung, D. C., Elford, A. R., & Jacquelot, N. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.03.008 · Cited by 1
Teruya, Y., Yamaguchi, K., Yamane, K., Miyake, N., Nakayama, Y., Nonaka, T., Chikumi, H., & Yamasaki, A. (2025) · Cells · doi:10.3390/cells14120893 · Cited by 1
Kumar, A., Bhargava, M., Dubey, U. S., & Dubey, B. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110883 · Cited by 1
ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes
Wang, H., Zhao, F., Li, Y., Wang, P., Wang, Y., Ren, P., Li, C., Zheng, H., Zeng, Z., & Pan, D. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0153 · Cited by 1
The Lytic Natural Killer Cell Immunological Synapse in Cancer
Fernandes, D. P., Filali, L., Huang, W., Hoffmann, C., & Thomas, C. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_49-1 · Cited by 1
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.